TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05534412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Academic Detailing
Description: 1. Provider Assessment. Physicians and advance practice providers will complete questionnaires before the intervention that assess their knowledge about the treatment for UI in women.~2. Mealtime Lecture. A group meeting will take place for the physicians in the intervention groups. All aspects of incontinence care will be addressed-including elements of the history and physical examination, initiation of conservative treatment, as well as when to refer for second-line therapies performed by specialists-utilizing the the principles of Academic Detailing.~3. Monthly individual feedback. Physicians and their clinical champion specialist will meet for individual coaching one month after the mealtime lecture to discuss and review the physician's previous performance as measured by the baseline chart abstraction. Physicians will have monthly check-ins with their clinical champion via a combination of quarterly synchronous Zooms and monthly asynchronous emails.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Clinical Decision Support
Description: Intervention physicians will have access to electronic clinical decision support consisting of note templates, order sets, interruptive alerts, and a notification of patients who screen positive for UI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APP Co-management
Description: To reduce additional burden of care on the PCPs, the investigators will incorporate Advanced Practices Providers into the patient education and self-management portion of care. The APPs will be trained together with the intervention physicians, but they will also undergo additional standardized training on patient education, UI knowledge, providing instruction on Kegel exercises, shared decision making, and self management.~Patients will then be scheduled for a UI education and self-management session with the APP by telemedicine (video visit or telephone visit) within one month of their initial visit. For patients in need of an annual pelvic examination, and if the patient's PCP prefers to have the APP conduct the pelvic exam, a separate visit will be scheduled with the APP. A followup televisit will then be scheduled within three months of the initial APP visit, in order to assess the outcome of non-surgical treatment and determine if a specialist referral is indicated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Referral
Description: In implementing the electronic consultation system in the private sector, the investigators will model the Expected Practice developed by the Los Angeles County Specialty-Primary Care Work Group. This eConsult system utilizes a kickback mechanism by which a specialist, who reviews the referral, can return it if it has not met certain baseline criteria (e.g. for a woman with OAB/urinary urgency: document negative UA, scheduled voids, titrate fluids to thirst, Kegels, antimuscarinics, optimize diuretic control, adjust any diuretics).
Study: NCT05718011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.5 micrograms/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.5 milligrams/kg diluted in 10mL of normal saline 0.9% given as IV infusion over 10 minutes
Study: NCT04558931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CellProtect
Description: In vitro expanded and activated autologous NK cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Naked immunoglobulin (Ig) G1 monoclonal antibody (mAb) that selectively binds to the human cell surface antigen molecule classified as cluster of differentiation (CD) 38
Study: NCT05012020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth Remote Monitoring platform
Description: Clinic Portal and Mobile Application for remote monitoring of Chronic Kidney Disease patients and patients on Peritoneal Dialysis
Study: NCT04786847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-TLX591
Description: TLX591, a monoclonal antibody HuX591 conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-TLX591)
Study: NCT05744960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication training
Description: Clinics will host an Announcement Approach Training (AAT) workshop. A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication training
Description: Clinics will host an Announcement Approach Training (AAT) workshop. A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: financial Incentive
Description: Clinics will host an AAT workshop, as in the other trial arm. Clinics in the intervention arm will then receive a 12-month clinic-level financial incentive program with predetermined targets for HPV vaccine initiation rates (5%, 10%, and 30% increases from baseline). Clinics will be notified of their HPV vaccination rates though a monthly, automated report. Clinic achievement will be assessed and incentives will be paid out to clinics monthly. Incentives will be tiered based on target and sized based on the number of clinic providers. For reaching the highest tier of 30%, clinics will receive an aggregate of $1000 per provider.
Study: NCT05771246

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic evaluation
Description: Panoramic and lateral cephalometric radiographs with cephalometric analysis will be performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic evaluation
Description: Panoramic and lateral cephalometric radiographs with cephalometric analysis will be performed.
Study: NCT05673057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
Description: Phase 1 comprises the dose-escalation part of the study and is designed to determine the recommended phase 2a dose regimen (RP2D-R) and/or the maximum tolerated dose-regimen (MTD-R) for MP0533 monotherapy.~Once the RP2D-R or MTD-R has been selected based on the dose escalation part, the study will proceed into the phase 2 expansion part and up to 30 additional patients will be treated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
Description: Phase 1 comprises the dose-escalation part of the study and is designed to determine the recommended phase 2a dose regimen (RP2D-R) and/or the maximum tolerated dose-regimen (MTD-R) for MP0533 monotherapy.~Once the RP2D-R or MTD-R has been selected based on the dose escalation part, the study will proceed into the phase 2 expansion part and up to 30 additional patients will be treated.
Study: NCT05038306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chinese medicine WT
Description: The Chinese medicine WT is thought to be neurotrophic, and its major constituent may benefit IGF-1 in animal studies, or certain healthy human group. WT is safe in clinical use in Asia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese medicine WT
Description: The Chinese medicine WT is thought to be neurotrophic, and its major constituent may benefit IGF-1 in animal studies, or certain healthy human group. WT is safe in clinical use in Asia.
Study: NCT06523140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boracare remote monitoring solution
Description: Bora Band wristband measuring vital signs at home, Bora Connect platform for caregiver visualization and BVS3 early detection of COPD exacerbations
Study: NCT05212220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMA-based intervention
Description: A personal quit plan includes (1) self-help techniques on handling craving; (2) suggestions to avoid the reported pro-smoking cues; (3) whether to quit progressively or abruptly; (4) referral for existing smoking cessation service; and (5) instruction of using over-the-counter (OTC) nicotine replacement therapy (NRT), if OTC-NRT is preferred by the participant will be designed and give to the participants via a nurse-led phone call.
Study: NCT04558931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isatuximab
Description: Naked immunoglobulin (Ig) G1 monoclonal antibody (mAb) that selectively binds to the human cell surface antigen molecule classified as cluster of differentiation (CD) 38
Study: NCT05212220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMA-based intervention
Description: Participants will receive 10-week tailored quitting reminder instant messages via WhatsApp and voluntarily discuss their quit plan with the research staff.
Study: NCT06002672

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: Control group. To the control group was assigned lettuce without any change in salinity but with the same characteristic of eustress lettuce (soil, water, harvesting time).
Description: Lettuce without any eustress was assigned to each participant belonging to the control group which ate 100gr every day for 12 day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Eustress group. To the intervention Eustress group was assigned the eustress lettuce.
Description: 100gr of eustress lettuce were assigned to each participant belonging to the intervention group which ate 100 grams every day for a total of 12 days
Study: NCT05706831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combinatory effect of music stimulation and neurostimulation
Description: music

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combinatory effect of music stimulation and neurostimulation
Description: music

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combinatory effect of music stimulation and neurostimulation
Description: music
Study: NCT06424522

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Fiber
Description: Receive dietary fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Fiber
Description: Receive dietary fiber

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enema Administration
Description: Undergo RRE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide Hydrochloride
Description: Receive loperamide hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide Hydrochloride
Description: Receive loperamide hydrochloride

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Undergo pelvic floor physical therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Undergo pelvic floor physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo abdominal film x-ray
Study: NCT05354115

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel
Description: Collection procedure will be a mid-turbinate nasal swab (deep nasal swab), by turning the swab five times in each nostril. After the nasal sampling, the operators will collect two nasopharyngeal swab one from each nostril of each subject.
Study: NCT06141005

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrathin bronchoscopy with intratumoral washing
Description: Each subject suspected or diagnosed of lung cancer will undergo bronchoscopic procedure. First, ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Then, intratumoral washing is performed. Subsequently, transbronchial lung biopsy is performed under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance.
Study: NCT05770882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Subjects will receive a single dose of chidamide. 5mg tablet. One dose every three days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Subjects will receive a single dose of Regorafenib. 40mg tablet. One dose daily.
Study: NCT04274361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion
Study: NCT05499546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCALE EYE
Description: Polyp size measurement using the SCALE EYE functionality
Study: NCT04856163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telelactation support
Description: Participants will get unlimited access (through 24 weeks postpartum) to video calls with lactation consultants who are available 24/7. Participants can use the service as demanded.
Study: NCT06077409

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin To Skin
Description: Skin to Skin Contact Group The temperature of the environment where kangaroo care will be carried out will be adjusted between 22-26 degrees C. The mother will be allowed to disinfect her hands and warm them until her hand temperature is at least 34 C. Only the baby's diaper, hat and socks will be left behind, and the baby will be placed face down on the mother's chest, with its head upright and its legs under the breasts in a frog position. The baby's face will be turned towards the mother and eye contact will be made. The baby will be in an upright position between the mother's breasts and skin to skin with the mother.~Skin-to-skin contact will begin 5 minutes before blood collection, continue throughout the procedure, and kangaroo care will continue until 5 minutes after the procedure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gentle Human Touch
Description: Experimental Group (Gentle Touch/Gentle Human Touch-GHT); After the mother is dressed in a clean apron, her hands are washed and disinfected, and it is safe to warm the hand temperature with a non-contact thermometer device until the measured value is 34 ºC. The mother, who was previously informed about the method, will be placed on the eyebrow line with the crown piece that will separate the fingertips and tuft of one hand, while the other hand will be placed on the lower abdomen, which will mark the waist and hips (Figure 1). The blood collection amount of GHT application will be started 5 minutes before, make sure that the blood collection is done and the blood collection will continue until 5 minutes later.
Study: NCT05140694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin 10 mg p.o. once daily (available to control over \~25mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Dulaglutide 0.75mg s.c. once a week (available to control over \~1.5mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin and Dulaglutide
Description: Empagliflozin 10 mg p.o. once daily with Dulaglutide 0.75mg s.c. once weekly
Study: NCT05335967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management program
Description: The self-management group will receive the self-management program for 12 weeks, including a self-management application, a self-management manual, and Professional support.

Intervention type: OTHER
Group type: OTHER
Intervention: Information package
Description: The patients in this group will receive an information package on a healthy diet.
Study: NCT04681469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: For all patient's population:~* Niraparib 200 mg/day: day -49 to day -21;~* Dostarlimab 500 mg iv: day -49 and day -28; At day -21, clinical evaluation will be performed and the patient will be directed to surgery with exclusion from the study in case of progressive disease. Radiological assessment will be performed according to the physician's judgement.~If no clinical evidence of disease progression:~* Niraparib 200 mg/day: day -21 to day -7~* Dostarlimab 500 mg iv: day -7~* Radiological assessment (day -1, ± 3 days),~* Surgery (original margin) at day 0 (±3 days)~* Standard postoperative (chemo)radiotherapy according to pathologic report;~* Maintenance Niraparib, 200 mg/day for 6 months~* Maintenance Dostarlimab, 500 mg iv q3W for the first four cycles and 1000 mg iv Q6W thereafter for 3 months.
Study: NCT06141291

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein diet
Description: Test the ability of high protein diet (1.4 g protein/kg/day) with branched chain amino acid and cysteine supplementation to decrease bed rest induced muscle atrophy, glutathione depletion and insulin resistance in old subjects.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: OGTT
Description: Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OGTT
Description: Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: OGTT
Description: Assessment of changes in insulin sensitivity (Oral Glucose Tolerance test and muscle insulin signalling: immunofluorescence and western blot of GLUT-4, IRS-1, MPP/TIMP, etc.) following bed rest in old and young subjects.
Study: NCT05972538

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osstell ( Osstell AB, Goteborg, Sweden).
Description: Implant stability were assessed on 15, 30,60 and 90 days of prosthesis delivery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osstell ( Osstell AB, Goteborg, Sweden).
Description: Implant stability were assessed on 15, 30,60 and 90 days of prosthesis delivery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: periodontal probe (Vivacare, TPS, Vivadent, Schaan, Lichtenstein
Description: Clinical evaluation included assessment of pocket depth, plaque index and bleeding on probing) around the implant abutments on 15, 30,60 and 90 days of prosthesis delivery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: periodontal probe (Vivacare, TPS, Vivadent, Schaan, Lichtenstein
Description: Clinical evaluation included assessment of pocket depth, plaque index and bleeding on probing) around the implant abutments on 15, 30,60 and 90 days of prosthesis delivery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire for patient satisfaction
Description: A questionnaire was used to evaluate patient satisfaction on 90 days at the end of follow up period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire for patient satisfaction
Description: A questionnaire was used to evaluate patient satisfaction on 90 days at the end of follow up period.
Study: NCT06146907

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive motor dual task exercises
Description: exercise program that combined motor tasks such as walking and juggling with cognitive task such as naming fruits or colors in the room.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exergaming
Description: Nintendo switch games that involve physical activity by participants to complete
Study: NCT04855474

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Intake
Description: Participants will consume hourly (8 hours) isoenergetic, isonitrogenous beverages containing one of the three protein intakes (0.2g/kg/d, 1.2 g/kg/d, 2.0g/kg/d) assigned in a randomized order between the three metabolic trials. Drinks will be enriched with stable isotope \[13C\]phenylalanine. The use of stable isotope \[13C\]phenylalanine will allow for the determination of the fate of AA in the body (incorporation into body protein or oxidation) which can be used to determine protein (AA) requirements.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Intake
Description: Participants will consume hourly (8 hours) isoenergetic, isonitrogenous beverages containing one of the three protein intakes (0.2g/kg/d, 1.2 g/kg/d, 2.0g/kg/d) assigned in a randomized order between the three metabolic trials. Drinks will be enriched with stable isotope \[13C\]phenylalanine. The use of stable isotope \[13C\]phenylalanine will allow for the determination of the fate of AA in the body (incorporation into body protein or oxidation) which can be used to determine protein (AA) requirements.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Intake
Description: Participants will consume hourly (8 hours) isoenergetic, isonitrogenous beverages containing one of the three protein intakes (0.2g/kg/d, 1.2 g/kg/d, 2.0g/kg/d) assigned in a randomized order between the three metabolic trials. Drinks will be enriched with stable isotope \[13C\]phenylalanine. The use of stable isotope \[13C\]phenylalanine will allow for the determination of the fate of AA in the body (incorporation into body protein or oxidation) which can be used to determine protein (AA) requirements.
Study: NCT05271630

Intervention type: OTHER
Intervention: Autologous Stem Cell Transplant
Description: This observational study will compare outcomes of prospectively enrolled ASCT recipients receiving Single agent vs doublet maintenance chemotherapy post ASCT

Intervention type: OTHER
Intervention: Autologous Stem Cell Transplant
Description: This observational study will compare outcomes of prospectively enrolled ASCT recipients receiving Single agent vs doublet maintenance chemotherapy post ASCT

Intervention type: DRUG
Intervention: Immunomodulatory Agent
Description: ASCT recipients receiving maintenance therapy consisting of an Immunomodulatory agent (IMID) after ASCT transplant

Intervention type: DRUG
Intervention: Immunomodulatory Agent
Description: ASCT recipients receiving maintenance therapy consisting of an Immunomodulatory agent (IMID) after ASCT transplant

Intervention type: DRUG
Intervention: Proteasome Inhibitor
Description: ASCT recipients receiving maintenance therapy with a proteasome inhibitor in combination with an immunomodulatory drug after ASCT transplant
Study: NCT06321601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Oral administration
Study: NCT04605341

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: miniplate
Description: comparison between k wires and miniplate in metacarpal fractures

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: miniplate
Description: comparison between k wires and miniplate in metacarpal fractures